Scienture Holdings, Inc. reported a net loss of $12.2 million for the nine months ended September 30, 2026, compared to a $13.4 million loss in the prior year. While revenues increased significantly to $1.65 million, the company remains focused on R&D and specialty pharmaceutical development following its acquisition of Scienture, LLC and the disposition of legacy subsidiaries.
Scienture Holdings held its 2026 Annual Meeting of Stockholders on October 28, 2026, where shareholders voted on four key proposals. Stockholders elected five directors to the board, ratified CM3 Advisory as the independent auditor for fiscal year 2026, and approved executive compensation on a non-binding advisory basis.
Scienture Holdings announced preliminary Q3 2026 revenue of approximately $1.22 million, a 256% sequential increase driven by the launch of REZENOPY and growth in Arbli sales. The company also reported regaining compliance with Nasdaq's minimum bid price requirement after its stock closed above $1.00 for ten consecutive trading days.
Scienture Holdings, Inc. implemented a 1-for-25 reverse stock split of its common stock effective October 5, 2026. The action is intended to increase the per-share price to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split reduces the outstanding share count from approximately 41.1 million to approximately 1.6 million shares.